These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 21518148

  • 1. A retrospective study to describe the incidence of moderate to severe allergic reactions to factor IX in subjects with haemophilia B.
    Recht M, Pollmann H, Tagliaferri A, Musso R, Janco R, Neuman WR.
    Haemophilia; 2011 May; 17(3):494-9. PubMed ID: 21518148
    [Abstract] [Full Text] [Related]

  • 2. Safe switching from a pdFIX (Immunine®) to a rFIX (Bax326).
    Solano Trujillo MH, Stasyshyn O, Rusen L, Serban M, Lamas JL, Perina FG, Urasinski T, Oh M, Knowlton WB, Valenta-Singer B, Pavlova BG, Abbuehl B.
    Haemophilia; 2014 Sep; 20(5):674-81. PubMed ID: 24720694
    [Abstract] [Full Text] [Related]

  • 3. Factor IX replacement to cover total knee replacement surgery in haemophilia B: a single-centre experience, 2000-2010.
    Uprichard J, Adamidou D, Goddard NJ, Mann HA, Yee TT.
    Haemophilia; 2012 Jan; 18(1):46-9. PubMed ID: 21545378
    [Abstract] [Full Text] [Related]

  • 4. A commentary on the differences in pharmacokinetics between recombinant and plasma-derived factor IX and their implications for dosing.
    Björkman S.
    Haemophilia; 2011 Mar; 17(2):179-84. PubMed ID: 21299739
    [Abstract] [Full Text] [Related]

  • 5. Recombinant factor IX recovery and inhibitor safety: a Canadian post-licensure surveillance study.
    Poon MC, Lillicrap D, Hensman C, Card R, Scully MF.
    Thromb Haemost; 2002 Mar; 87(3):431-5. PubMed ID: 11916075
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006).
    Chitlur M, Warrier I, Rajpurkar M, Lusher JM.
    Haemophilia; 2009 Sep; 15(5):1027-31. PubMed ID: 19515028
    [Abstract] [Full Text] [Related]

  • 8. Inhibitor development in haemophilia B: an orphan disease in need of attention.
    DiMichele D.
    Br J Haematol; 2007 Aug; 138(3):305-15. PubMed ID: 17614818
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A prospective registry of European haemophilia B patients receiving nonacog alfa, recombinant human factor IX, for usual use.
    Berntorp E, Keeling D, Makris M, Tagliaferri A, Male C, Mauser-Bunschoten EP, Musso R, Roca CA, Hassoun A, Kollmer C, Charnigo R, Baumann J, Rendo P.
    Haemophilia; 2012 Jul; 18(4):503-9. PubMed ID: 22044794
    [Abstract] [Full Text] [Related]

  • 12. Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates.
    Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL, Recombinant Factor IX Study Group.
    Blood; 2001 Dec 15; 98(13):3600-6. PubMed ID: 11739163
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B.
    Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC, Garzone PD, Schaub RG.
    Blood; 1996 Oct 01; 88(7):2603-10. PubMed ID: 8839853
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics, efficacy and safety of BAX326, a novel recombinant factor IX: a prospective, controlled, multicentre phase I/III study in previously treated patients with severe (FIX level <1%) or moderately severe (FIX level ≤2%) haemophilia B.
    Windyga J, Lissitchkov T, Stasyshyn O, Mamonov V, Rusen L, Lamas JL, Oh MS, Chapman M, Fritsch S, Pavlova BG, Wong WY, Abbuehl BE.
    Haemophilia; 2014 Jan 01; 20(1):15-24. PubMed ID: 23834666
    [Abstract] [Full Text] [Related]

  • 16. EQOFIX: a combined economic and quality-of-life study of hemophilia B treatments in France.
    Polack B, Calvez T, Chambost H, Rothschild C, Goudemand J, Claeyssens S, Borel-Derlon A, Bardoulat I, Maurel F, Woronoff-Lemsi MC, EQOFIX Study Group.
    Transfusion; 2015 Jul 01; 55(7):1787-97. PubMed ID: 25652955
    [Abstract] [Full Text] [Related]

  • 17. Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays.
    Wilmot HV, Hogwood J, Gray E.
    Haemophilia; 2014 Nov 01; 20(6):891-7. PubMed ID: 24800651
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetics of factor IX in hemophilia B patients undergoing surgery.
    Preijers T, Hazendonk HCAM, Liesner R, Chowdary P, Driessens MHE, Hart D, Keeling D, Laros-van Gorkom BAP, van der Meer FJM, Meijer K, Fijnvandraat K, Leebeek FWG, Collins PW, Cnossen MH, Mathôt RAA, OPTI‐CLOT study group.
    J Thromb Haemost; 2018 Nov 01; 16(11):2196-2207. PubMed ID: 30394056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.